Which exploits BP9a mediated TfR recognition for selective delivery of doxorubicin to malignant cells and enhances therapeutic index and mitigate off-target toxicity to normal tissues.112 In addition, the development of a novel T7-SN-38 PDC using the affinity of HAIYPRH (T7) peptide to TfR overexpressed on blood-brain barrier and glioma cells has also been recently reported.113. This evidence concerns the gene TFRC and central nervous system cancer.